Related Experiment Video
Updated: Jul 28, 2025

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
[Chinese expert consensus on integrated lipid management in HIV/AIDS]
Insights
Human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients face higher cardiovascular risks. This expert consensus provides guidance on integrated lipid management for these individuals on antiretroviral therapies (ART).
Area of Science:
- Cardiovascular Medicine
- Infectious Diseases
- Metabolic Disorders
Context:
- HIV/AIDS is a global health concern with increased cardiovascular disease (CVD) risk.
- Dyslipidemia is a key risk factor for cardiovascular events, prevalent in HIV/AIDS patients.
- Antiretroviral therapies (ART) and viral factors contribute to atherosclerotic coronary vascular disease (ASCVD) risk in this population.
Purpose:
- To establish an expert consensus on lipid management for HIV/AIDS patients in China.
- To address the lack of specific guidelines for lipid management in HIV/AIDS patients undergoing long-term ART.
- To integrate current knowledge on lipid metabolism, ASCVD risk factors, and ART in China.
Summary:
- This consensus addresses the elevated risk of cardiovascular diseases, particularly ASCVD, in HIV/AIDS patients.
- It emphasizes the importance of understanding lipid metabolism, managing conventional ASCVD risk factors, and optimizing lipid management strategies.
- The document is based on the current ART landscape in China and recent research findings.
Impact:
- Aims to improve the long-term prognosis and quality of life for HIV/AIDS patients.
- Provides a framework for healthcare professionals in China for integrated lipid management.
- Contributes to the specialized care of HIV/AIDS patients by addressing a critical comorbidity.
Abstract:
Human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) are one of the global public health issues concerning health of human beings. Dyslipidemia is one of the major risk factors for cardiovascular events, while elevation of plasma cholesterol levels is associated with the onset of over 50% coronary heart disease. The incidence risks of cardiovascular diseases are higher in HIV/AIDS patients than those in normal populations. In addition to conventional risk factors, viral duplication and suboptimal treatments increase risks of atherosclerotic coronary vascular disease (ASCVD) in HIV/AIDS patients. Thus, a deep knowledge of lipid metabolism and dysregulation profiles, an efficient control of conventional ASCVD risk factors, as well as strengthened measures to lipid management, are of significance to improve long-term prognosis and life quality for HIV/AIDS patients. However, up to date, there is no particular consensus on lipid management for HIV/ADIS populations under long-term antiretroviral therapies (ART). Hereby, based on current status quo of ART in China and frontier achievements of fundamental researches and clinical trials, we invited domestic experts in fields of infectious diseases and cardiovascular diseases to compose this expert consensus on the integrated management of lipid in HIV/AIDS patients in China.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Retrovirus Life Cycles
Coronary Artery Disease IV: Preventive Measures
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...

